Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
Xiaofeng Chen(Ningbo University), Yongqian Shu(Jiangsu Province Hospital), Xiangcheng Li(Wuhan University of Technology), Yan Shi(Hebei Provincial Center for Disease Control and Prevention), Jingrong Qiu(Second Military Medical University), Jiuwei Cui(Jilin University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Zhou(University of Toledo), Jianyi Zhao(Jiangsu Province Hospital), Shiqing Chen, Zhaoxia Wang(Shanghai Jiao Tong University), Xue Li(Qingdao Agricultural University), Jing Liu(Shanghai Jiao Tong University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Deqiang Wang(Jiangsu University), Liuqing Zhu, Lanlan Pan(Jiangsu Province Hospital), Yunpeng Liu(Shenyang Institute of Automation), Haizhou Lou(Sir Run Run Shaw Hospital), Fengjiao Zhao(Jiangsu Province Hospital), Dongqin Zhu(Wake Forest University), Yang Shao(Sanya University)
Cited by 66
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
|Biomarker Research|2020|473